Graham Richards joins Science Advisory Panel at Oxford Medical Diagnostics
News Jan 24, 2011
Oxford Medical Diagnostics, a developer of advanced diagnostic technology for rapid, accurate and low-cost diagnosis and monitoring of disease and metabolic functions, announces today that Professor Graham Richards is joining the company’s Science Advisory Panel.
Professor Richards brings his considerable expertise in life sciences. He has also contributed to the success of a number of technology-based start-up companies and will be able to advise the company on its development strategy.
“Graham Richards boosts the scientific excellence in the Oxford Medical Diagnostics team and will provide valuable input on our development strategy,” said Oxford Medical Diagnostics CEO, Tony Marchington. “Our Science Advisory Panel includes leading international scientists and a wide range of experience in the science and technology field.”
Professor Richards was a co-founder of one of Oxford University’s most successful spin-offs, along with Marchington. The company, Oxford Molecular Group plc, reached a FTSE 250 valuation of GBP 475 million. Professor Richards is one of the leading computational chemists in the UK, with over 300 publications. He served as Chairman of the Department of Chemistry at Oxford University from 1997 to 2007. He is head of the Centre for Computational Drug Discovery at Oxford. Throughout his career, Professor Richards has been involved in the commercialization of technologies. In 2001, he founded InhibOx Ltd. He was a director of ISIS Innovation Ltd, the University of Oxford's technology transfer company and was involved for several years with the Wellcome Trust in a similar capacity. He is also a main board director (formerly chairman) of IP Group plc, the listed intellectual property commercialization company.
Potential Barcode Identified for a Form of Alcoholic Liver DiseaseNews
NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.READ MORE
Enterome and Nestlé Health Sciences Launch New Diagnostics CompanyNews
Enterome and Nestlé Health Sciences join to create Microbiome Diagnostics Partners, a company that will enable the development and diagnostics for multiple diseases including inflammatory bowel diseases (IBD) and liver diseases.READ MORE
Comments | 0 ADD COMMENT
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018
EMBL Course: Introduction to Metabolomics Analysis
Mar 20 - Mar 23, 2018